TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA ...
REFINE data showed patients with resistant and refractory migraine have a higher burden of comorbidities than those with nonresistant and nonrefractory migraine.
For risk-reducing mastectomy, improved outcomes were seen whether or not the germline BRCA mutation was present in the BRCA1 or BRCA2 gene. “These findings are critical for improving the counseling of ...
Patients with axial spondyloarthritis (axSpA) reported greater improvements in spinal symptoms and mobility over 2 years compared against those with non-axSpA chronic back pain, though impairments ...